Epalrestat-d5

CAT: 0804-HY-W653944Size: 5 mgDry Ice: NoHazardous: No
CAT#:0804-HY-W653944Size:5 mg
Selected
PRICE
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
Epalrestat-d5 is deuterium labeled Epalrestat. Epalrestat is an orally active aldose reductase inhibitor that acts on diabetic neuropathy[1][2][3][4].
CAS Number
[2755644-33-6]
Product Name Alternative
ONO2235-d5
UNSPSC
12352005
Target
Aldose Reductase; Isotope-Labeled Compounds
Type
Reference compound
Related Pathways
Metabolic Enzyme/Protease; Others
Field of Research
Metabolic Disease
Smiles
O=C(N1CC(O)=O)/C(SC1=S)=C/C(C)=C/C2=C(C([2H])=C(C([2H])=C2[2H])[2H])[2H]
Molecular Formula
C15H8D5NO3S2
Molecular Weight
324.43
References & Citations
[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53 (2) :211-216.|[2]Ramirez, M.A. and N.L. Borja, Epalrestat: an aldose reductase inhibitor for the treatment of diabetic neuropathy. Pharmacotherapy, 2008. 28 (5) : p. 646-55.|[3]He J, et al. The aldose reductase inhibitor epalrestat exerts nephritic protection on diabetic nephropathy in db/db mice through metabolic modulation. Acta Pharmacol Sin. 2019 Jan;40 (1) :86-97.|[4]Okamoto, H., et al., Effects of epalrestat, an aldose reductase inhibitor, on diabetic neuropathy and gastroparesis. Intern Med, 2003. 42 (8) : p. 655-64.|[5]Sato K, et al. Epalrestat increases intracellular glutathione levels in Schwann cells through transcription regulation. Redox Biol. 2013 Nov 19;2:15-21.|[6]Hotta, N., et al., Clinical investigation of epalrestat, an aldose reductase inhibitor, on diabetic neuropathy in Japan: multicenter study. Diabetic Neuropathy Study Group in Japan. J Diabetes Complications, 1996. 10 (3) : p. 168-72.|[7]Li QR, et al. Epalrestat protects against diabetic peripheral neuropathy by alleviating oxidative stress and inhibiting polyol pathway. Neural Regen Res. 2016 Feb;11 (2) :345-51.|[8]Zhang T, et al. The Aldose Reductase Inhibitor Epalrestat Maintains Blood-Brain Barrier Integrity by Enhancing Endothelial Cell Function during Cerebral Ischemia. Mol Neurobiol. 2023 Jul;60 (7) :3741-3757.
Shipping Conditions
Room temperature
Scientific Category
Isotope-Labeled Compounds
Clinical Information
No Development Reported

Related Products

CatalogName
HY-66009-01Epalrestat
HY-66009R-01Epalrestat (Standard)
HY-W717221Medetomidine-d5 (d5-Major)
HY-151913S-01Sebuthylazine-d5 (ethyl-d5)
HY-133171AS-01(S) -Norfluoxetine-d5 (phenyl-d5)
HY-151910S1(±) -Fluoxetine-d5 Oxalate (phenyl-d5)
HY-133171AS1-01(R) -Norfluoxetine-d5 Phthalimide (Phenyl-d5)
HY-W758414Phoxim-d5 (phenyl-d5) (mixture of isomers)
HY-W782193-01Sulcatone-d5
HY-W745615-01Triundecanoin-d5

Alternative Products

CatalogName
TRC-E565302-5MGEpalrestat-d5
TRC-E565300-1GEpalrestat

Popular Products